Supersaturated Oxygen (SSO2) Therapy in STEMI Treatments

Published: 06 December 2021

  • Views:

    Views Icon 7614
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 3 | Session 3 of 3
    Questions and Answers
    Nadia Sutton, Suzanne de Waha, Dan Burkhoff, Babar Basir, Jay Traverse
    Up Next
  • episode_image
    Part 2 | Session 6 Questions and Answers Dan Burkhoff, Richard Schatz, Steven Yakubov, Andreas Schäfer
Average (ratings)
No ratings
Your rating

Overview

Despite advances in reperfusion with primary stenting, progress in STEMI outcomes has stalled over the past 20 years. With 90% of coronary blood flow in the capillaries, the answer might be in the microvasculature. TherOx SSO2 Therapy is the first FDA approved therapy shown to significantly reduce the infarct size in STEMI patients.

 

During this series of webinars on Supersaturated Oxygen (SSO2) Therapy, our faculty of renowned international experts will discuss and dissect the mechanisms and data around this promising new therapy for STEMI patients.

This broadcast series is supported by

Key Objectives

  • Understand how SSO2 Therapy works
  • Hear about trends in STEMI treatment
  • Explore the role of microvascular obstruction and infarct size in outcomes
  • Understand the science behind SSO2 Therapy

Target Audience

This series is designed for the entire cardiology community:

  • Interventional Cardiologists
  • Cardiologists
  • Clinical Fellows and Trainees

More from this programme

Part 1

Supersaturated Oxygen Therapy (SSO2): The Next Frontier in STEMI Treatment

Part 2

SSO2 Therapy in STEMI to Reduce Infarct Size: A Conversation with Global Thought Leaders

Learn about this promising new therapy for STEMI patients and hear from global thought leaders, Dr Dan Burkhoff, Dr Steven Yakubov, Dr Andreas Schäfer and Dr Richard Schatz, about their experiences with it.

Part 3

Infarct Size, Microvascular Obstruction and Outcomes in STEMI: An Expert Panel Discussion

Learn about which patients are at greatest risk of microvascular obstruction (MVO) and large infarcts, how we can diagnose MVO and how we can treat MVO and infarct. Moderated by Dr Nadia Sutton, hear global thought leaders Dr Babar Basir, Dr Dan Burkhoff, Dr Suzanne de Waha and Dr Jay Traverse answer these questions.

Faculty Biographies

Nadia  Sutton

Nadia Sutton

Assistant Professor and Interventional Cardiologist

Dr Nadia Sutton is an Assistant Professor, interventional cardiologist and vascular biologist in the Division of Cardiovascular Medicine and the Frankel Cardiovascular Center at University of Michigan, Michigan, US.

 

View full profile
Suzanne  de Waha

Suzanne de Waha

Dr Suzanne de Waha works at University Heart Center, Luebeck, DE.

Her main focus is acute myocardial infarction (STEMI + NSTEMI), cardiac imaging including CMR, cardiogenic shock, assist devices, interventional cardiology and structural heart disease including TAVI.

Dr de Waha has >150 publications in peer-reviewed, international high-ranked journals.

View full profile
Dan Burkhoff

Dan Burkhoff

Director

Dr Dan Burkhoff is currently the Director of Heart Failure, Hemodynamics and MCS Research at Cardiovascular Research Foundation, New York, US. Dr Burkhoff's interest include cardiovascular modelling and ventricular mechanics, cardiovascular monitoring, heart failure, device and pharmacologic treatments for heart failure, including left ventricular assist devices. He is also author of Harvi, an interactive simulation-based application for teaching and researching on ventricular mechanics and hemodynamics.

View full profile
Babar Basir

Babar Basir

Interventional Cardiologist

Dr Babar Basir is an Interventional Cardiologist at the Henry Ford Hospital in Detroit, Michigan, US.

Dr Basir specialises in the treatment of complex heart blockage with minimally invasive techniques using balloons and stents. He is a national leader in the treatment of cardiogenic shock and lectures around the world on the use of temporary heart pumps when the heart is failing. 

View full profile
Jay Traverse

Jay Traverse

Senior Consulting Cardiologist

Dr Jay Traverse is a senior consulting cardiologist at Minneapolis Heart Institute, Minnesota, US. He is also the Director of Research at MHIF and an Associate Professor of Medicine at the University of Minnesota School of Medicine, Minnesota, US.

His special interests include interventional cardiology, stem cell therapy, biomaterials, and ischemia/reperfusion injury.

View full profile